Helsinki-based startup IXI has emerged from stealth with $36.5 million in Series A funding to develop smart, low-power prescription glasses. The company aims to disrupt the $200 billion eyewear market by integrating eye-tracking and liquid crystal lens technology, allowing frames to automatically adjust focus for users with presbyopia.
A Heavyweight Backing for Vision Tech
The latest funding round was led by the London-based venture capital firm Plural, with notable participation from the Amazon Alexa Fund, Tesi, byFounders, Heartcore, Eurazeo, FOV Ventures, and Tiny Supercomputer. This influx of capital positions IXI to accelerate the development of its first commercial product, moving beyond the research and development phase.
Beyond the VR Hype
Founded by Niko Eiden and Ville Miettinen—veterans of Nokia’s mobile tech and the mixed-reality firm Varjo—IXI is intentionally distancing itself from the crowded and struggling VR/AR headset market. While tech giants have poured billions into head-mounted displays, consumer adoption has remained stagnant.
“There really aren’t that many trying to use technology to actually fix eyesight,” says CEO Niko Eiden. Unlike smart glasses designed for social media or navigation, IXI’s focus is strictly medical: enhancing the user’s ability to see clearly without the need for constant lens changes or clumsy progressive glasses.
The Technology Under the Hood
While specific technical details remain under wraps due to pending patents, the core mechanism involves a miniature device embedded in the frame. This hardware tracks eye movement in real-time, signaling the liquid crystal lenses to shift focus instantly.
Management suggests that the glasses will be priced similarly to high-end consumer electronics rather than traditional bifocals. With an estimated battery life of two days, the lenses are designed to default to a near-sighted prescription, ensuring that the wearer maintains basic distance vision even if the device runs out of power.
Competitive Landscape and Market Potential
The path to market is notoriously difficult. Competitors like Elcyo, Laclarée, and Vixion have struggled to balance aesthetic design with functional autofocus capabilities. Vixion, for instance, has released devices that retain a bulky, camera-lens-like appearance.
Amazon’s interest in the startup is particularly strategic. Beyond its current marketplace for readers, the e-commerce giant has been exploring specialized eyewear for logistics and is expanding aggressively into the pharmacy sector. By supporting IXI, Amazon is positioning itself at the intersection of medical device innovation and mass-market hardware.
What Comes Next
IXI plans to unveil its prototype later this year. While the company has not yet provided a firm launch date—as the product will require medical device certification—the team remains focused on proving that their “invisible” technology can provide a permanent, high-tech solution to age-related vision degradation.